← Browse by Condition
Medical Condition

transient ischemic attack

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 3, Phase 2

ClinicalMetric tracks all active clinical trials for transient ischemic attack sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — transient ischemic attack Clinical Trials

How many clinical trials are currently recruiting for transient ischemic attack?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for transient ischemic attack, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for transient ischemic attack?
transient ischemic attack research spans Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a transient ischemic attack clinical trial?
Eligibility criteria for transient ischemic attack trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
2
Phase 3
1
Top Sponsors
Mazandaran University of Medical Sciences 1 trial
University of Zurich 1 trial
University College Dublin 1 trial

Recruiting Clinical Trials

NCT06653348 Phase 2, Phase 3
Recruiting
Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
Enrollment
100 pts
Location
Iran
Sponsor
Mazandaran University of Medic...
View Trial →
NCT06443268
Recruiting
Cerebrovascular Disease: Quality of Life (CODE: QoL)
Enrollment
680 pts
Location
Switzerland
Sponsor
University of Zurich
View Trial →
NCT04647292 Phase 2
Recruiting
European Blood Pressure Intensive Control After Stroke
Enrollment
142 pts
Location
Ireland
Sponsor
University College Dublin
View Trial →

Related Conditions

ischemic stroke (2) quality of life (1) stroke acute (1) sexual behavior (1) stress (1) cortisol excess (1) incontinence urinary (1) caregiver burden (1) intracerebral hemorrhage (1) cerebrovascular disorders (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology